Satoshi Kubo Selected Research

Cilomilast

1/2012	Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.
1/2012	Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
6/2011	ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satoshi Kubo Research Topics

Disease

35	Rheumatoid Arthritis 01/2021 - 01/2011
10	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 04/2011
7	Inflammation (Inflammations) 01/2019 - 06/2011
6	Immunoglobulin G4-Related Disease 01/2022 - 01/2018
6	Autoimmune Diseases (Autoimmune Disease) 01/2020 - 09/2016
5	Systemic Scleroderma (Systemic Sclerosis) 04/2020 - 01/2016
4	Pathologic Processes 01/2020 - 11/2013
3	Pulmonary Arterial Hypertension 11/2022 - 01/2020
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 06/2018
3	Psoriatic Arthritis 01/2022 - 01/2019
3	Churg-Strauss Syndrome (Allergic Angiitis) 01/2022 - 01/2021
3	Fibrosis (Cirrhosis) 01/2022 - 01/2020
3	Neoplasms (Cancer) 01/2019 - 01/2018
2	Mixed Connective Tissue Disease (MCTD) 11/2022 - 01/2020
2	Vasculitis (Vasculitides) 01/2022 - 01/2021
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 04/2018
2	Arthritis (Polyarthritis) 01/2021 - 01/2012
2	Eosinophilia 01/2020 - 01/2012
2	Necrosis 02/2019 - 12/2014
2	Hyperplasia 01/2019 - 04/2018
2	Pleural Effusion (Pleural Effusions) 08/2018 - 04/2018
2	Pleural Tuberculosis 08/2018 - 04/2018
2	Ischemic Stroke 03/2018 - 06/2017
2	Hepatocellular Carcinoma (Hepatoma) 01/2015 - 07/2005
2	Asthma (Bronchial Asthma) 01/2012 - 01/2012
2	Vomiting 01/2012 - 06/2011
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2012 - 05/2011
1	Infections 01/2022
1	Muscular Diseases (Myopathy) 11/2021
1	Dermatomyositis (Dermatopolymyositis) 11/2021
1	Bone Resorption 01/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2021
1	Stupor 04/2020
1	Empty Sella Syndrome 04/2020
1	Interstitial Lung Diseases (Interstitial Lung Disease) 04/2020
1	Hypertension (High Blood Pressure) 04/2020
1	Esophageal Motility Disorders (Nutcracker Esophagus) 04/2020
1	Sclerosis 04/2020
1	Contracture 04/2020

Drug/Important Bio-Agent (IBA)

10	Janus Kinase InhibitorsIBA 01/2021 - 01/2012
7	Abatacept (Orencia)FDA Link 01/2018 - 01/2014
6	AntibodiesIBA 11/2022 - 01/2013
6	tofacitinibIBA 01/2021 - 01/2012
6	Biological ProductsIBA 01/2020 - 09/2014
5	Immunoglobulin G (IgG)IBA 01/2022 - 08/2018
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2016
5	3- (4- (3- chlorophenyl)- 1- ethyl- 7- methyl- 2- oxo- 1,2- dihydro- 1,8- naphthyridin- 3- yl)propanoic acidIBA 01/2012 - 05/2011
4	AutoantibodiesIBA 12/2021 - 01/2013
4	Adalimumab (Humira)FDA Link 09/2020 - 06/2012
4	GlucocorticoidsIBA 01/2020 - 02/2014
4	Rituximab (Mabthera)FDA Link 01/2020 - 04/2011
4	Pharmaceutical PreparationsIBA 01/2019 - 01/2016
4	RoflumilastIBA 01/2012 - 06/2011
3	InterleukinsIBA 01/2022 - 12/2014
3	Tumor Necrosis Factor InhibitorsIBA 01/2022 - 01/2018
3	baricitinibIBA 01/2021 - 09/2016
3	Janus KinasesIBA 01/2021 - 12/2014
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2019
3	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 04/2020 - 01/2018
3	SteroidsIBA 10/2019 - 01/2015
3	Monoclonal AntibodiesIBA 01/2019 - 04/2018
3	InterferonsIBA 01/2019 - 06/2012
3	CilomilastIBA 01/2012 - 06/2011
3	Phosphodiesterase 4 InhibitorsIBA 01/2012 - 05/2011
2	mepolizumabIBA 01/2022 - 01/2021
2	Interleukin-22 (IL-22)IBA 01/2022 - 01/2018
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2022
2	CytokinesIBA 01/2022 - 01/2012
2	AntigensIBA 01/2021 - 01/2012
2	CollagenIBA 04/2020 - 05/2018
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2020 - 01/2020
2	Antirheumatic Agents (DMARD)IBA 01/2020 - 11/2016
2	Interleukin-23 (Interleukin 23)IBA 01/2019 - 04/2018
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 11/2016
2	Adenosine DeaminaseIBA 08/2018 - 04/2018
2	Interleukin-12 (IL 12)IBA 06/2018 - 04/2018
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2015 - 01/2013
2	Interleukin-10 (Interleukin 10)IBA 12/2014 - 01/2012
1	CX3C Chemokine Receptor 1IBA 01/2022
1	GTP Phosphohydrolases (GTPases)IBA 01/2022
1	Fc gamma receptor IIBIBA 01/2022
1	Chemokine CX3CL1IBA 01/2022
1	nuclear matrix protein 2IBA 11/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	Certolizumab Pegol FDA Link 01/2021
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021
1	amsonic acid (DAS)IBA 09/2020
1	Growth Hormone (Somatotropin)IBA 04/2020
1	Follicle Stimulating Hormone (Follitropin)FDA Link 04/2020
1	Luteinizing Hormone (Lutropin)FDA LinkGeneric 04/2020
1	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 04/2020
1	Collagen Type VIIBA 04/2020
1	Carbon MonoxideIBA 01/2020
1	TabletsIBA 01/2020
1	Vasodilator Agents (Vasodilators)IBA 01/2020
1	peficitinibIBA 01/2020
1	ras ProteinsIBA 01/2020

Therapy/Procedure

18	Therapeutics 01/2022 - 04/2011
1	Remission Induction 01/2022
1	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 04/2020